Oppenheimer analyst Jeff Jones raised the firm’s price target on Kymera Therapeutics to $56 from $52 and keeps an Outperform rating on the shares following the recent financing and the firm’s continued enthusiasm for Kymera’s platform. Oppenheimer continues to view Kymera as the leader in developing targeted protein degraders for inflammation and immunology indications, with its portfolio of best-in-class oral molecules positioned to challenge standard-of-care injectable options across several large indications, and the firm remain enthusiastic on the story with multiple clinical readouts anticipated in 2025 which could provide substantial upside in the year ahead, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics presents data for KT-621 at EADV Congress
- Kymera assumed with Outperform from Market Perform at Leerink
- Boeing’s Starliner to return without astronauts: Morning Buzz
- Kymera upgraded, MoonLake downgraded: Wall Street’s top analyst calls
- Wolfe upgrades Kymera Therapeutics, calls ‘great long-term trade’